Epidemiologic Characteristics Determining the Choice of Direct-Acting Antiviral Therapy in HCV Patients: An Italian Real-World Evidence Study

Pangenotypic direct-acting antivirals (pDAAs) have transformed hepatitis C virus (HCV) treatment. In Italy, sofosbuvir/velpatasvir (SOF/VEL) and glecaprevir/pibrentasvir (GLE/PIB) are available. While both show similar efficacy, differences in patient profiles and potential drug–drug interactions (D...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Nicola Pugliese, Fabio Conti, Valerio Rosato, Paolo Gallo, Stefano Gitto, Marco Riglietta, Francesca Frigerio, Valentina Perrone, Chiara Veronesi, Maria Cappuccilli, Luca Degli Esposti, Alessandra Mangia, Loreta A. Kondili
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2025-11-01
Serija:	Pathogens
Teme:	drug–drug interactions (DDIs) glecaprevir/pibrentasvir hepatitis C virus (HCV) pangenotypic direct-acting antivirals sofosbuvir/velpatasvir
Online dostop:	https://www.mdpi.com/2076-0817/14/11/1177
Oznake:	Označite Brez oznak, prvi označite!